Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers

作者：Liu, Dongdong; Li, Beibei; Shi, Xiaoshun; Zhang, Jiexia; Chen, Allen Menglin; Xu, Jiarui; Wang, Wan; Huang, Kailing; Gao, Jinwei; Zheng, Zhouxia; Liu, Dan; Wang, Huimin; Shi, Wen; Chen, Lin; Xu, Jianhua^*

来源：Aging-US, 2021, 13(3): 4258-4273.

• breast cancer
• biomarkers
• non-coding RNA
• exosome
• hsa-miR-423-5p

Introduction: Circulating non-coding RNA is an ideal source to discover novel biomarkers for non-invasive screening. However, studies for the discovery of universal miRNAs in serum and exosomes for breast cancer early diagnosis are limited. @@@ Methods: Based on bioinformatic analysis, in vitro and in vivo studies were performed to understand the role of identified hsa-miR-423-5p in cancer proliferation, migration, cancer stem cell properties. Next, global non-coding RNA expression profiles in blood serum and exosome were performed. hsa-miR-423-5p expression from a total of 356 peripheral blood samples was evaluated and the association of hsa-miR-423-5p expression with clinical characteristics, sensitivity and specificity for breast cancer diagnosis were assessed. @@@ Results: The expression of serum and exosomal hsa-miR-423-5p is abnormally increased in breast cancer. Suppression of hsa-miR-423-5p inhibited cell proliferation and invasion in both T47D and MDA-MB-231 breast cancer cell lines, and tumor growth in vivo. Compared with 113 healthy women, quantification analysis of hsa-miR-423-5p in 224 breast cancer samples confirmed the abnormal expression. Serum hsamiR-423-5p was significantly associated with the clinical stage (P=0.001) and Ki-67 level (P=0.004). @@@ Conclusions: A translational bioinformatics analysis procedure and validation by in vitro, in vivo, and clinical samples reveal that hsa-miR-423-5p could be used as a non-invasive breast cancer biomarker.

• 单位
  1; 广州中医药大学; 广州医学院; 南方医科大学